Market Place
Sourcing Support
Harrow’s ImprimisRx Receives $34.9M Jury Verdict in Lawsuit
21 Nov 2024 //
BUSINESSWIRE
Harrow Announces Participation in Upcoming Investor Conferences
15 Nov 2024 //
BUSINESSWIRE
Harrow Launches Affordability Program with Price Reductions
13 Nov 2024 //
BUSINESSWIRE
Harrow Announces Q3 2024 Financial Results
13 Nov 2024 //
BUSINESSWIRE
Harrow Announces Market Access Wins for VEVYE®
12 Nov 2024 //
BUSINESSWIRE
Harrow Partners with Asembia to Enhance Eyecare Products Support
07 Nov 2024 //
BUSINESSWIRE
Harrow to Report Q3 2024 Results After Market Close on Nov 13
31 Oct 2024 //
BUSINESSWIRE
Harrow Relaunches TRIESENCE®
03 Oct 2024 //
BUSINESSWIRE
BC Fails To Provide Essential Medication Coverage
25 Sep 2024 //
BUSINESSWIRE
Harrow to Present at Three Investor Conferences in September in New York
03 Sep 2024 //
BUSINESSWIRE
Harrow Announces Second Quarter 2024 Financial Results
07 Aug 2024 //
BUSINESSWIRE
Harrow To Report Q2 2024 Results On August 7
25 Jul 2024 //
BUSINESSWIRE
Harrow to Attend 2024 ASRS Annual Meeting
12 Jul 2024 //
BUSINESSWIRE
Harrow Enters 340B Contract With Apexus For Key Products
09 Jul 2024 //
BUSINESSWIRE
Harrow Provides TRIESENCE® Relaunch Update
20 Jun 2024 //
BUSINESSWIRE
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
05 Jun 2024 //
BUSINESSWIRE
Harrow to Present at Two Investor Conferences in May
15 May 2024 //
BUSINESSWIRE
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
13 May 2024 //
BUSINESSWIRE
Harrow Announces First Quarter 2024 Financial Results
13 May 2024 //
BUSINESSWIRE
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
19 Mar 2024 //
BUSINESSWIRE
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results
05 Mar 2024 //
BUSINESSWIRE
Harrow Licenses Canadian Rights to Apotex for Ophthalmic Products
15 Feb 2024 //
BUSINESSWIRE
Harrow Announces New Appointments to its Board of Directors
29 Jan 2024 //
BUSINESSWIRE
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%
11 Jan 2024 //
BUSINESSWIRE
Harrow Partners with Leading Healthcare Market Access Technology Platforms
03 Jan 2024 //
BUSINESSWIRE
Harrow Completes Transfer of the TRIESENCE® New Drug Application
29 Nov 2023 //
BUSINESSWIRE
Harrow Announces Third Quarter 2023 Financial Results
13 Nov 2023 //
BUSINESSWIRE
Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023
30 Oct 2023 //
BUSINESSWIRE
Harrow Completes Transfer of NDAs and Launches FLAREX®
24 Oct 2023 //
BUSINESSWIRE
Harrow Announces Second Quarter 2023 Financial Results
09 Aug 2023 //
BUSINESSWIRE
Harrow Launches VIGAMOX® in the U.S.
31 Jul 2023 //
BUSINESSWIRE
Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023
26 Jul 2023 //
BUSINESSWIRE
Harrow Prices $60 Million Public Offering of Common Stock
19 Jul 2023 //
BUSINESSWIRE
Harrow prices $60M offering one day after acquiring rights to dry eye treatment
19 Jul 2023 //
ENDPTS
Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE from Novaliq
18 Jul 2023 //
BUSINESSWIRE
Harrow Announces Proposed Public Offering of Common Stock
18 Jul 2023 //
BUSINESSWIRE
Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance
18 Jul 2023 //
BUSINESSWIRE
Harrow to Participate in 23rd Annual Institutional Investor Conference
17 May 2023 //
BUSINESSWIRE
Harrow Announces First Quarter 2023 Financial Results
11 May 2023 //
BUSINESSWIRE
Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society
04 May 2023 //
BUSINESSWIRE
Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023
27 Apr 2023 //
BUSINESSWIRE
Harrow Announces New $100 Million Secured Credit Facility with Oaktree
28 Mar 2023 //
BUSINESSWIRE
Harrow Announces Fourth Quarter and Year-End 2022 Financial Results
23 Mar 2023 //
BUSINESSWIRE
Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO
13 Mar 2023 //
BUSINESSWIRE
Harrow Announces Appointment of Mark Mannebach as Head of Regulatory Affairs
06 Mar 2023 //
BUSINESSWIRE
Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023
02 Mar 2023 //
BUSINESSWIRE
Harrow Launches Next-Generation Compounded Atropine Formulations
15 Feb 2023 //
BUSINESSWIRE
Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO
02 Feb 2023 //
BUSINESSWIRE
Harrow Closes Acquisition of U.S. Rights to ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, and TRIESENCE
23 Jan 2023 //
BUSINESSWIRE
Harrow Announces Availability of Fortisite™ Formulations for In-Office Use
05 Jan 2023 //
BUSINESSWIRE
Harrow Secures Capital to Close Recently Announced Acquisition
16 Dec 2022 //
BUSINESSWIRE
Novartis, busy with its restructuring, sells 5 eye drugs for up to $175M
15 Dec 2022 //
FIERCEPHARMA
Harrow Prices $25 Million Offering
14 Dec 2022 //
BUSINESSWIRE
Harrow Announces Proposed Offering of $100 Million of Senior Notes
14 Dec 2022 //
BUSINESSWIRE
Harrow and iOR Partners Expand National Product Supply Agreement
30 Nov 2022 //
BUSINESSWIRE
Harrow Announces Third Quarter 2022 Financial Results
14 Nov 2022 //
BUSINESSWIRE
Harrow Launches Atropine.com
10 Nov 2022 //
BUSINESSWIRE
Harrow Announces U.S. FDA Approval of IHEEZO
27 Sep 2022 //
BIOSPACE
Harrow Announces U.S. FDA Approval of IHEEZO
27 Sep 2022 //
BUSINESSWIRE
Harrow Health to Announce Q2 2022 Financial Results on August 9, 2022
27 Jul 2022 //
BUSINESSWIRE
